JP2014519480A - 癌で使用される抗ｉｌ−１ｒ１阻害物質 - Google Patents

癌で使用される抗ｉｌ−１ｒ１阻害物質 Download PDF

Info

Publication number
JP2014519480A
JP2014519480A JP2014505330A JP2014505330A JP2014519480A JP 2014519480 A JP2014519480 A JP 2014519480A JP 2014505330 A JP2014505330 A JP 2014505330A JP 2014505330 A JP2014505330 A JP 2014505330A JP 2014519480 A JP2014519480 A JP 2014519480A
Authority
JP
Japan
Prior art keywords
csc
tumor
cells
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2014505330A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014519480A5 (enExample
Inventor
アニタ セシレ
ミヒャエル ヴォルフ
ロバート タイ
ヘレン サブゼバーリ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2014519480A publication Critical patent/JP2014519480A/ja
Publication of JP2014519480A5 publication Critical patent/JP2014519480A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
JP2014505330A 2011-04-15 2012-04-13 癌で使用される抗ｉｌ−１ｒ１阻害物質 Abandoned JP2014519480A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11003183 2011-04-15
EP11003183.8 2011-04-15
PCT/US2012/033490 WO2012142391A1 (en) 2011-04-15 2012-04-13 Anti- il-1r1 inhibitors for use in cancer

Publications (2)

Publication Number Publication Date
JP2014519480A true JP2014519480A (ja) 2014-08-14
JP2014519480A5 JP2014519480A5 (enExample) 2015-06-11

Family

ID=46018101

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014505330A Abandoned JP2014519480A (ja) 2011-04-15 2012-04-13 癌で使用される抗ｉｌ−１ｒ１阻害物質

Country Status (8)

Country Link
US (1) US20140308294A1 (enExample)
EP (1) EP2697260A1 (enExample)
JP (1) JP2014519480A (enExample)
CN (1) CN103492416A (enExample)
AU (1) AU2012242666A1 (enExample)
CA (1) CA2833147A1 (enExample)
IL (1) IL228847A0 (enExample)
WO (1) WO2012142391A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020519590A (ja) * 2017-05-08 2020-07-02 エムエービー ディスカバリー ゲーエムベーハー 炎症症状で使用するための抗ｉｌ−１ｒ３抗体

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009120903A2 (en) 2008-03-26 2009-10-01 Cellerant Therapeutics, Inc. Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
CN108026172B (zh) 2015-06-26 2022-04-29 赛诺菲生物技术公司 单克隆抗il-1racp抗体
US9856291B2 (en) * 2015-12-08 2018-01-02 Agricultural Technology Research Institute Cancer stem cell targeting peptide and use thereof
EP3241845A1 (en) * 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
AU2018232727A1 (en) * 2017-03-10 2019-10-31 Merck Patent Gmbh Infected cell cultures
US11248054B2 (en) 2017-06-12 2022-02-15 Bluefin Biomedicine, Inc. Anti-IL1RAP antibodies and antibody drug conjugates
CA3101736A1 (en) * 2018-05-29 2019-12-05 Oncohost Ltd Cancer treatment by blocking host-induced il-1 in combination with radiotherapy
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
CN109468380B (zh) * 2018-10-31 2022-05-17 复旦大学附属肿瘤医院 Il1r2在乳腺癌预后评估与靶向治疗中的应用
US20220233710A1 (en) * 2019-05-20 2022-07-28 Nantong Yichen Biopharma. Co. Ltd. Bispecific molecule and preparation and use thereof
AR130550A1 (es) 2022-09-21 2024-12-18 Sanofi Biotechnology Anticuerpo anti-il-1r3 humanizado y métodos de uso

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU9803037D0 (en) 1988-05-27 1999-11-29 Synergen Inc Interleukin-1 inhibitors
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US20030007972A1 (en) * 1999-02-24 2003-01-09 Edward Tobinick Cytokine antagonists and other biologics for the treatment of bone metastases
HUP0203689A3 (en) 1999-12-10 2005-01-28 Amgen Inc Thousand Oaks Interleukin-1 receptor antagonist-like molecules and uses thereof
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
DK2213685T3 (en) * 2002-09-06 2014-03-03 Medarex Llc Therapeutic anti-IL-1R1 monoclonal antibody
AR045614A1 (es) 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
JP4931919B2 (ja) 2005-06-21 2012-05-16 ゾーマ テクノロジー リミテッド ＩＬ−１β結合抗体およびその断片
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
WO2010089707A1 (en) * 2009-02-04 2010-08-12 Yeda Research And Development Co. Ltd. Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy
GB2472856B (en) * 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020519590A (ja) * 2017-05-08 2020-07-02 エムエービー ディスカバリー ゲーエムベーハー 炎症症状で使用するための抗ｉｌ−１ｒ３抗体
JP7315472B2 (ja) 2017-05-08 2023-07-26 サノフィ・バイオテクノロジー 炎症症状で使用するための抗ｉｌ－１ｒ３抗体
JP2023134618A (ja) * 2017-05-08 2023-09-27 サノフィ・バイオテクノロジー 炎症症状で使用するための抗ｉｌ－１ｒ３抗体
JP7605916B2 (ja) 2017-05-08 2024-12-24 サノフィ・バイオテクノロジー 炎症症状で使用するための抗ｉｌ－１ｒ３抗体

Also Published As

Publication number Publication date
EP2697260A1 (en) 2014-02-19
IL228847A0 (en) 2013-12-31
WO2012142391A1 (en) 2012-10-18
CN103492416A (zh) 2014-01-01
AU2012242666A1 (en) 2013-11-28
CA2833147A1 (en) 2012-10-18
US20140308294A1 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
JP2014519480A (ja) 癌で使用される抗ｉｌ−１ｒ１阻害物質
Bocca et al. Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model
Argyle et al. Targeting macrophage-recruiting chemokines as a novel therapeutic strategy to prevent the progression of solid tumors
Phillips et al. The stromal derived factor–1/CXCL12–CXC chemokine receptor 4 biological axis in non–small cell lung cancer metastases
Kryczek et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers
Vieira et al. A crucial role for TNF‐α in mediating neutrophil influx induced by endogenously generated or exogenous chemokines, KC/CXCL1 and LIX/CXCL5
US20120219561A1 (en) Prophylaxis Against Cancer Metastasis
CN104853774B (zh) Il-20拮抗剂用于治疗肝脏疾病
US11197890B2 (en) Methods of treating cancer, infectious disease, and autoimmune disease using CXC chemokines
JP2018516881A (ja) 癌治療のためのｎｋ細胞および抗体
CN113018438A (zh) Cxcr2抑制剂在制备治疗鼻咽癌的药物中的用途
US8518401B1 (en) Treating inflammatory diseases with antibodies that inhibit fractalkine-CXCR1 interaction
CN107299138B (zh) Cxcl4单抗治疗肿瘤及化疗后肿瘤加速再增殖基因筛选法
KR102693317B1 (ko) 암 면역요법을 위한, 활성화되고 확장된 자연 킬러 세포와 조합된 항-cxcr4 항체
CN121443626A (zh) 修饰的 γδ T细胞
CN119562815A (zh) Gpcr抑制剂及其用途
US20180002441A1 (en) Methods of increasing delivery of anti-cancer agents to targets
FI131561B1 (en) CLEVER-1 INHIBITOR TO PROMOTE HEMATOLOGICAL RECOVERY WHEN USING CHEMOTHERAPY
ES2381195T3 (es) Inhibidor de elastasa en leucimia
US20110123524A1 (en) Methods for treating hematopoietic malignancies
US20250197513A1 (en) Osmr-specific monoclonal antibodies and methods of their use
US20150023920A1 (en) Novel compositions and methods for preventing or treating cancer metastasis
Bernardini et al. The Role of Chemoattractants in the Tumor Microenvironment
Giese Engineering IPSC-derived Neutrophils for Enhanced Effector Function
US20220106402A1 (en) Antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150413

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150413

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20150417